Abstract
Small heterodimer partner (SHP, NR0B2) is a nuclear receptor that exerts influence over the expression of several nuclear receptors and transcription factors. We have previously shown that SHP is involved in several metabolic and cellular processes. Of particular interest, SHP appears to play a crucial role as a tumor suppressor. We have recently published work demonstrating that SHP knockout (SHP-/-) mice spontaneously develop hepatocellular carcinoma. We have discovered that SHP is a potent inhibitor of cellular proliferation, and that activation of SHP induces apoptosis and inhibits tumor growth. In collateral studies, we have also found that SHP is a key regulator of microRNA gene transcription and through this process can activate apoptosis. Furthermore, we have also shown that SHP expression can be influenced by the degree of methylation. The ability to modulate key cellular processes, particularly cellular proliferation and apoptosis, has heightened interest in the ability of this protein to function as a therapeutic target in hepatomas, as well as other neoplasms. Future research will also examine the sensitivity and specificity of SHP to function as a biomarker for hepatocellular carcinoma.
Keywords: Nuclear receptor, gene transcription, cell cycle, apoptosis, liver cancer.
Current Cancer Therapy Reviews
Title:Nuclear Receptor SHP as a Potential Therapeutic Target for Liver Cancer
Volume: 6 Issue: 4
Author(s): Jenny Hatch, Shiguo Liu, Timothy Gayowski, John Sorensen and Li Wang
Affiliation:
Keywords: Nuclear receptor, gene transcription, cell cycle, apoptosis, liver cancer.
Abstract: Small heterodimer partner (SHP, NR0B2) is a nuclear receptor that exerts influence over the expression of several nuclear receptors and transcription factors. We have previously shown that SHP is involved in several metabolic and cellular processes. Of particular interest, SHP appears to play a crucial role as a tumor suppressor. We have recently published work demonstrating that SHP knockout (SHP-/-) mice spontaneously develop hepatocellular carcinoma. We have discovered that SHP is a potent inhibitor of cellular proliferation, and that activation of SHP induces apoptosis and inhibits tumor growth. In collateral studies, we have also found that SHP is a key regulator of microRNA gene transcription and through this process can activate apoptosis. Furthermore, we have also shown that SHP expression can be influenced by the degree of methylation. The ability to modulate key cellular processes, particularly cellular proliferation and apoptosis, has heightened interest in the ability of this protein to function as a therapeutic target in hepatomas, as well as other neoplasms. Future research will also examine the sensitivity and specificity of SHP to function as a biomarker for hepatocellular carcinoma.
Export Options
About this article
Cite this article as:
Hatch Jenny, Liu Shiguo, Gayowski Timothy, Sorensen John and Wang Li, Nuclear Receptor SHP as a Potential Therapeutic Target for Liver Cancer, Current Cancer Therapy Reviews 2010; 6 (4) . https://dx.doi.org/10.2174/157339410793358084
DOI https://dx.doi.org/10.2174/157339410793358084 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Carbon Nanotubes: An Emerging Drug Delivery Carrier in Cancer Therapeutics
Current Drug Delivery A Mechanistic Overview on Male Infertility and Germ Cell Cancers
Current Pharmaceutical Design Alpha-1 Antitrypsin: It’s Role in Health and Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Cancer and Aids: New Trends in Drug Design and Chemotherapy
Current Computer-Aided Drug Design Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis
Current Drug Metabolism Heat Shock Proteins in Cancer: Signaling Pathways, Tumor Markers and Molecular Targets in Liver Malignancy
Protein & Peptide Letters Compounds From Celastraceae Targeting Cancer Pathways and Their Potential Application in Head and Neck Squamous Cell Carcinoma: A Review
Current Genomics Breast Cancer, a Stem Cell Disease
Current Stem Cell Research & Therapy Base-Modified Nucleosides as Chemotherapeutic Agents: Past and Future
Current Topics in Medicinal Chemistry Diketoacid Inhibitors of HIV-1 Integrase: From L-708,906 to Raltegravir and Beyond
Current Medicinal Chemistry Synergistic Effect of α-Solanine and Cisplatin Induces Apoptosis and Enhances Cell Cycle Arrest in Human Hepatocellular Carcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Cyclooxygenase-2 (COX-2) - A Therapeutic Target in Liver Cancer?
Current Pharmaceutical Design EGFR and the Complexity of Receptor Crosstalk in the Cardiovascular System
Current Molecular Medicine Glioblastoma Tumor Initiating Cells: Therapeutic Strategies Targeting Apoptosis and MicroRNA Pathways
Current Molecular Medicine Angiogenesis in Chronic Lymphocytic Leukemia
Current Angiogenesis (Discontinued) Intracellular Calcium, Endothelial Cells and Angiogenesis
Recent Patents on Anti-Cancer Drug Discovery Current Status of Magnetite-Based Core@Shell Structures for Diagnosis and Therapy in Oncology Short running title: Biomedical Applications of Magnetite@Shell Structures
Current Pharmaceutical Design Biomolecules of Human Female Fertility - Potential Therapeutic Targets for Pharmaceutical Design
Current Pharmaceutical Design Network Effect of Wt-mutant p53 Interactions and Implications on p53 Gene Therapy
Current Pharmaceutical Design Somatic Mutations, Viral Integration and Epigenetic Modification in the Evolution of Hepatitis B Virus-Induced Hepatocellular Carcinoma
Current Genomics